COMMODORE CAPITAL LP 13D and 13G filings for Cogent Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:05 pm Purchase | 2024-09-30 | 13G | Cogent Biosciences, Inc. COGT | COMMODORE CAPITAL LP | 10,497,990 9.300% | 4,325,904 (+70.09%) | Filing |
| 2024-02-14 4:05 pm Purchase | 2023-12-31 | 13G | Cogent Biosciences, Inc. COGT | COMMODORE CAPITAL LP | 6,172,086 7.100% | 1,246,086 (+25.30%) | Filing |
| 2023-02-14 4:05 pm Purchase | 2022-12-31 | 13G | Cogent Biosciences, Inc. COGT | COMMODORE CAPITAL LP | 4,926,000 7.000% | 2,644,685 (+115.93%) | Filing |
| 2022-02-14 4:07 pm Purchase | 2021-12-31 | 13G | Cogent Biosciences, Inc. COGT | COMMODORE CAPITAL LP | 2,281,315 5.700% | 139,976 (+6.54%) | Filing |
| 2021-11-03 5:31 pm Purchase | 2021-10-07 | 13G | Cogent Biosciences, Inc. COGT | COMMODORE CAPITAL LP | 2,141,339 5.400% | 2,141,339 (New Position) | Filing |